Cargando…

Health and Economic Outcomes of Home Maintenance Allergen Immunotherapy in Select Patients with High Health Literacy during the COVID-19 Pandemic: A Cost-Effectiveness Analysis During Exceptional Times

BACKGROUND: Allergen immunotherapy (AIT) is safe and effective but is typically administered under strict clinic observation to mitigate the risk of a systemic reaction to immunotherapy (SRIT). However, in the setting of the global coronavirus disease 2019 pandemic, alternative care models should be...

Descripción completa

Detalles Bibliográficos
Autores principales: Shaker, Marcus S., Mosnaim, Giselle, Oppenheimer, John, Stukus, David, Abrams, Elissa M., Greenhawt, Matthew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7224677/
https://www.ncbi.nlm.nih.gov/pubmed/32417446
http://dx.doi.org/10.1016/j.jaip.2020.05.007
_version_ 1783533949121724416
author Shaker, Marcus S.
Mosnaim, Giselle
Oppenheimer, John
Stukus, David
Abrams, Elissa M.
Greenhawt, Matthew
author_facet Shaker, Marcus S.
Mosnaim, Giselle
Oppenheimer, John
Stukus, David
Abrams, Elissa M.
Greenhawt, Matthew
author_sort Shaker, Marcus S.
collection PubMed
description BACKGROUND: Allergen immunotherapy (AIT) is safe and effective but is typically administered under strict clinic observation to mitigate the risk of a systemic reaction to immunotherapy (SRIT). However, in the setting of the global coronavirus disease 2019 pandemic, alternative care models should be explored. OBJECTIVE: To evaluate the cost-effectiveness of home immunotherapy self-administration (HITSA) in a highly idealized circumstance for provision of maintenance AIT in a shelter-in-place or other scenarios of unforeseen reduction in nonessential medical services. METHODS: Markov modeling was used to compare in-office clinic AIT in selected patients using cohort analysis and microsimulation from the societal and health care perspectives. RESULTS: Assuming similar SRIT rates, HITSA was found to be a cost-effective option with an incremental cost-effectiveness ratio of $44,554/quality-adjusted life-year when considering both incremental epinephrine autoinjector costs and coronavirus disease 2019 risks. Excluding epinephrine autoinjector costs, HISTA dominated other options. However, outside of pandemic considerations, HITSA was not cost-effective (incremental cost-effectiveness ratio, $198,877,286) at annual epinephrine autoinjector costs above $287. As the incremental HITSA SRIT rate increased above 15%, clinic AIT was the most cost-effective strategy. Excluding both pandemic risks and risk of motor vehicle accident fatality from round-trip clinic transit, clinic AIT dominated other strategies. Clinic AIT was the more cost-effective option at very high fatality relative risk for HITSA or at very low annual risk of contracting coronavirus disease 2019. CONCLUSIONS: Under idealized assumptions HITSA can be a safe and cost-effective option during a global pandemic in appropriately selected patients provided home rates of SRIT remain stable.
format Online
Article
Text
id pubmed-7224677
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology
record_format MEDLINE/PubMed
spelling pubmed-72246772020-05-15 Health and Economic Outcomes of Home Maintenance Allergen Immunotherapy in Select Patients with High Health Literacy during the COVID-19 Pandemic: A Cost-Effectiveness Analysis During Exceptional Times Shaker, Marcus S. Mosnaim, Giselle Oppenheimer, John Stukus, David Abrams, Elissa M. Greenhawt, Matthew J Allergy Clin Immunol Pract Original Article BACKGROUND: Allergen immunotherapy (AIT) is safe and effective but is typically administered under strict clinic observation to mitigate the risk of a systemic reaction to immunotherapy (SRIT). However, in the setting of the global coronavirus disease 2019 pandemic, alternative care models should be explored. OBJECTIVE: To evaluate the cost-effectiveness of home immunotherapy self-administration (HITSA) in a highly idealized circumstance for provision of maintenance AIT in a shelter-in-place or other scenarios of unforeseen reduction in nonessential medical services. METHODS: Markov modeling was used to compare in-office clinic AIT in selected patients using cohort analysis and microsimulation from the societal and health care perspectives. RESULTS: Assuming similar SRIT rates, HITSA was found to be a cost-effective option with an incremental cost-effectiveness ratio of $44,554/quality-adjusted life-year when considering both incremental epinephrine autoinjector costs and coronavirus disease 2019 risks. Excluding epinephrine autoinjector costs, HISTA dominated other options. However, outside of pandemic considerations, HITSA was not cost-effective (incremental cost-effectiveness ratio, $198,877,286) at annual epinephrine autoinjector costs above $287. As the incremental HITSA SRIT rate increased above 15%, clinic AIT was the most cost-effective strategy. Excluding both pandemic risks and risk of motor vehicle accident fatality from round-trip clinic transit, clinic AIT dominated other strategies. Clinic AIT was the more cost-effective option at very high fatality relative risk for HITSA or at very low annual risk of contracting coronavirus disease 2019. CONCLUSIONS: Under idealized assumptions HITSA can be a safe and cost-effective option during a global pandemic in appropriately selected patients provided home rates of SRIT remain stable. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology 2020 2020-05-14 /pmc/articles/PMC7224677/ /pubmed/32417446 http://dx.doi.org/10.1016/j.jaip.2020.05.007 Text en © 2020 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Original Article
Shaker, Marcus S.
Mosnaim, Giselle
Oppenheimer, John
Stukus, David
Abrams, Elissa M.
Greenhawt, Matthew
Health and Economic Outcomes of Home Maintenance Allergen Immunotherapy in Select Patients with High Health Literacy during the COVID-19 Pandemic: A Cost-Effectiveness Analysis During Exceptional Times
title Health and Economic Outcomes of Home Maintenance Allergen Immunotherapy in Select Patients with High Health Literacy during the COVID-19 Pandemic: A Cost-Effectiveness Analysis During Exceptional Times
title_full Health and Economic Outcomes of Home Maintenance Allergen Immunotherapy in Select Patients with High Health Literacy during the COVID-19 Pandemic: A Cost-Effectiveness Analysis During Exceptional Times
title_fullStr Health and Economic Outcomes of Home Maintenance Allergen Immunotherapy in Select Patients with High Health Literacy during the COVID-19 Pandemic: A Cost-Effectiveness Analysis During Exceptional Times
title_full_unstemmed Health and Economic Outcomes of Home Maintenance Allergen Immunotherapy in Select Patients with High Health Literacy during the COVID-19 Pandemic: A Cost-Effectiveness Analysis During Exceptional Times
title_short Health and Economic Outcomes of Home Maintenance Allergen Immunotherapy in Select Patients with High Health Literacy during the COVID-19 Pandemic: A Cost-Effectiveness Analysis During Exceptional Times
title_sort health and economic outcomes of home maintenance allergen immunotherapy in select patients with high health literacy during the covid-19 pandemic: a cost-effectiveness analysis during exceptional times
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7224677/
https://www.ncbi.nlm.nih.gov/pubmed/32417446
http://dx.doi.org/10.1016/j.jaip.2020.05.007
work_keys_str_mv AT shakermarcuss healthandeconomicoutcomesofhomemaintenanceallergenimmunotherapyinselectpatientswithhighhealthliteracyduringthecovid19pandemicacosteffectivenessanalysisduringexceptionaltimes
AT mosnaimgiselle healthandeconomicoutcomesofhomemaintenanceallergenimmunotherapyinselectpatientswithhighhealthliteracyduringthecovid19pandemicacosteffectivenessanalysisduringexceptionaltimes
AT oppenheimerjohn healthandeconomicoutcomesofhomemaintenanceallergenimmunotherapyinselectpatientswithhighhealthliteracyduringthecovid19pandemicacosteffectivenessanalysisduringexceptionaltimes
AT stukusdavid healthandeconomicoutcomesofhomemaintenanceallergenimmunotherapyinselectpatientswithhighhealthliteracyduringthecovid19pandemicacosteffectivenessanalysisduringexceptionaltimes
AT abramselissam healthandeconomicoutcomesofhomemaintenanceallergenimmunotherapyinselectpatientswithhighhealthliteracyduringthecovid19pandemicacosteffectivenessanalysisduringexceptionaltimes
AT greenhawtmatthew healthandeconomicoutcomesofhomemaintenanceallergenimmunotherapyinselectpatientswithhighhealthliteracyduringthecovid19pandemicacosteffectivenessanalysisduringexceptionaltimes